Back

Anti-SARS-CoV-2 antibodies seroprevalence among patients submitted to treatment for tuberculosis in Rio de Janeiro, Brazil: a cross-sectional study.

Gomes, K. M.; Leite, S. P.; Moutinho, M. H. V.; Souza, T. A. d.; Batista, R. d. C.; Oliveira, L. C. M. d.; Redner, P.; Ramos, J. P.; Rocha, F. M. G. d.; Oliveira, G. P. d.; Teva, A.; Motta, F. d. C.; Siqueira, M. A. M. T. d.; Duarte, R. S.; Bastos, F. I. P. M.; Viana, P. V. d. S.

2021-11-19 epidemiology
10.1101/2021.11.17.21266274 medRxiv
Show abstract

Due to tuberculosis (TB) patients pulmonary damages, some authors believe that a SARS-CoV-2 coinfection may result in unfavorable outcomes. A cross-sectional anti-SARS-CoV-2 antibodies seroprevalence study was conducted at a TB treatment tertiary referral unit in Rio de Janeiro, Brazil, to estimate the proportion (in %) of TB patients exposed to the new coronavirus and their main outcomes. Of 83 patients undergoing TB treatment, 26.5% have already been infected by the new coronavirus. Most patients were asymptomatic (69%) or had mild COVID-19 cases (31%). Only one patient required hospitalization. Among the symptoms and signs presented, the most frequently reported were: fever, headache, and myalgia. People with less education and less purchasing power seemed to had been more exposed to SARS-CoV-2.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.